MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.09
-2.79
-5.71%
Closed 19:53 08/11 EDT
OPEN
49.07
PREV CLOSE
48.88
HIGH
49.39
LOW
46.02
VOLUME
856.22K
TURNOVER
--
52 WEEK HIGH
58.00
52 WEEK LOW
30.76
MARKET CAP
7.51B
P/E (TTM)
-19.6865
1D
5D
1M
3M
1Y
5Y
Legend Biotech Sees Adjusted Loss in H1
Legend Biotech Sees Adjusted Loss in H1
MT Newswires · 6d ago
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
SOMERSET, N.J., August 04, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of...
Business Wire · 08/04 20:01
Analysts Say These 3 Stocks Are Their Top Picks for the Rest of 2022
Farewell, July, it’s been a pleasure. Sentiment might finally be turning on Wall Street after the stock market recorded its best month since November 2020, buoyed by the tech giants better-than-expected quarterly results and the prospect of the Fed easing ...
TipRanks · 07/31 10:23
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?
Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 07/28 12:30
Legend Biotech to raise $350M in stock offering
Legend Biotech (NASDAQ:LEGN) <a href="https://seekingalpha.co...
Seekingalpha · 07/27 10:04
Legend Biotech Prices Offering at $43/ADS, Expects Gross Proceeds of $350 Million
Legend Biotech Prices Offering at $43/ADS, Expects Gross Proceeds of $350 Million
MT Newswires · 07/27 04:02
BRIEF-Legend Biotech Corp Says Public Offering Of 8.14 Mln ADSs Priced At $43/Ads
BRIEF-Legend Biotech Corp Says Public Offering Of 8.14 Mln ADSs Priced At $43/Ads
Reuters · 07/27 00:06
Legend Biotech Corporation Announces Pricing of Public Offering
SOMERSET, N.J., July 27, 2022--July 2022 Follow-On Pricing Announcement
Business Wire · 07/27 00:00
More
No Data
Learn about the latest financial forecast of LEGN. Analyze the recent business situations of Legend Biotech Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LEGN stock price target is 66.86 with a high estimate of 75.00 and a low estimate of 53.00.
High75.00
Average66.86
Low53.00
Current 46.09
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 165
Institutional Holdings: 55.39M
% Owned: 35.91%
Shares Outstanding: 162.87M
TypeInstitutionsShares
Increased
68
8.44M
New
25
1.44M
Decreased
31
7.79M
Sold Out
22
1.28M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Chairman/Director
Fangliang Zhang
Chief Executive Officer/Director
Ying Huang
Chief Financial Officer
Lori Macomber
Senior Vice President
Meeta Chatterjee
Senior Vice President
Guowei Fang
Director
Ye Wang
Director
Li Zhu
Independent Director
Patrick Casey
Independent Director
Tomas Heyman
Independent Director
Xiaohui Ji
Independent Director
Li Mao
Independent Director
Corazon Sanders
Independent Director
Wai Man Yau
No Data
No Data
About LEGN
Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The Company is also developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL. It also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.

Webull offers kinds of Legend Biotech Corp stock information, including NASDAQ:LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.